Floatz logo

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER

Recurrent Childhood Lymphoblastic Lymphoma

Children's Oncology Groupprotein_peptidePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

84 Active assets in the Recurrent Childhood Lymphoblastic Lymphoma cohort.

Asset / SponsorPhaseRating
Cladribine
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase 4BBB
ASPARAGINASE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 4BBB
PEGASPARGASE
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 4BBB
ETOPOSIDE
University of Washington
Phase 4BBB

View all 50 →

Same molecule, other indications

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:

psoriasisDormant
BBB
Indicative ·
76 / 100
View asset →
Pancreatitis, Chronic; Diabetes; TransplantDormant
BB
Indicative ·
68 / 100
View asset →
skin carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →